Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03890185
Other study ID # 2121 063
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 1, 2012
Est. completion date December 31, 2020

Study information

Verified date January 2019
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.


Description:

Nasopharyngeal cancer is the commonest cancer of the head and neck in Saudi Arabia and constitutes nearly a half (44%) of all head and neck cancers diagnosed annually according to the National Cancer Registry Data. Majority of our patients present with locally advance disease which adversely affect their treatment outcome. The treatment of this disease has evolved over the last several years and several Phase III trials have now shown that combined chemotherapy and radiation are significantly superior to treatment with radiation therapy alone. However, results for treatment of the Stage III and IV disease remains less than satisfactory with a 5-year survival of 60-70 %. Recent data in other head and neck cancer sites including nasopharyngeal cancer indicates that the use of chemotherapy in combination with radiation may improve the outcome of therapy primarily by a reduction in the rate of distant metastasis. Induction chemotherapy alone has, however, failed to show an improvement in survival compared to radiation therapy alone. The administration of induction chemotherapy followed by concurrent chemo-radiation appears the most promising approach. Our experience at KFSH&RC with induction chemotherapy followed by chemo-radiation in Stage IV cancers, still reveals that approximately 25- 30% of patients will develop local relapse in the nasopharyngeal site; and 35- 40 % of patients are likely to develop distant metastasis. The most promising recent schedule of induction chemotherapy has been the use of Docetaxel and Cisplatin followed by concurrent Cisplatin and radiation. A recent Phase II study demonstrated that the three-year progression-free survival and overall survivals was improved with the use of this induction regimen. A variety of treatment strategies are currently being investigated in hope of achieving improved local control and enhanced survival of patients. These include addition of new chemotherapy drugs, other targeted agents such as Bevacizumab, Cetuximab, etc and radiation fractionation. The rationale for using neoadjuvant chemotherapy is that a reduction in the overall tumor burden will permit more effective local therapy and reduce the rates of distant metastases. Neoadjuvant cisplatin / docetaxel are active agents for locally advanced nasopharyngeal cancer. The addition of docetaxel to platinum containing neoadjuvant chemotherapy in other locally advanced head and neck squamous-cell carcinoma have also been shown to improve survival.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 108
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. WHO II-III carcinoma of the nasopharynx, histologically proven.

2. Locally advanced stage III and IV (minimal intracranial extension only) with absence of distant metastases.

3. Age between 18 and 70 years.

4. ECOG performance status 0-2.

5. Hematological function parameters performed within 10 days before inclusion:

- Neutrophils = 1000 * 109/l.

- Platelets: = 100 * 109/l.

- Hemoglobin: = 9 g/dl

6. Adequate hepatic function, defined as follows within 2 weeks prior to registration:

- Total bilirubin is normal

- AST (SGOT) and ALT (SGPT) <= 2.5 * upper limit of normal (ULN) of each center.

- Alkaline phosphatase <= 2.5 * ULN.

7. Renal function parameters performed within 10 days before inclusion: normal serum creatinine and creatinine clearance must be = 55 ml/min.

8. Patient who has given his/her written consent before any specific procedure of the protocol.

Exclusion Criteria:

1. Patients who present stage I, IIa, IIb and IVc.

2. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix are all permissible);

3. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is permitted;

4. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.

5. Head and neck surgery of the primary tumor or lymph nodes prior to registration, with the exception of incisional or excisional biopsies.

6. Patients receiving other experimental therapeutic cancer treatment;

7. Blood pressure at baseline > 150/100 mmHg;

8. Peripheral neuropathy CTCAE, v. 4.0 h grade 2

9. Severe, active co-morbidity, defined as follows:

- Major medical or psychiatric illness, which in the investigators' opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy.

- Unstable angina and/or congestive heart failure or peripheral vascular disease requiring hospitalization within the last 12 months, or other cardiac compromise that in the judgment of the investigator will preclude the safe administration of a study drug.

- Acquired Immune Deficiency.

- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.

- Prior allergic reaction to the study drug(s) involved in this.

Study Design


Intervention

Combination Product:
Chemo + Low dose RT
Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
Drug:
Chemo alone
Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of chemo and radiation toxicities Chemotherapy and acute radiation toxicities as evaluated using the revised NCI (CTCAE) Version 4.03 Three years
Secondary Distant and loco regional failure Distant and loco regional failure as evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) Three years
See also
  Status Clinical Trial Phase
Completed NCT00370890 - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase 3
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Completed NCT00697619 - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer Phase 2
Completed NCT00078546 - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Phase 1
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT01074021 - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Phase 3
Not yet recruiting NCT04158414 - Applying PET/MR in Oncology - a Prospective Project N/A
Completed NCT02608073 - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer Phase 2
Completed NCT03656250 - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04476641 - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT06414577 - Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy Phase 2
Recruiting NCT03003182 - A Study of Nasopharyngeal Carcinoma From Guangdong N/A
Not yet recruiting NCT06349889 - Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Phase 2
Completed NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Not yet recruiting NCT05305131 - Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer Phase 2
Completed NCT01800071 - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Phase 1
Recruiting NCT00304694 - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients N/A
Recruiting NCT05638269 - A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China